Evidence map›Paper›PMID 28161142›Full record

ArticleJournal of substance abuse treatment2018

Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.

Brantley P Jarvis, Anthony DeFulio, Lauren Long, August F Holtyn, Annie Umbricht, Michael Fingerhood, George E Bigelow, Kenneth Silverman

Abstract read
In one paragraph

Article in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Development of a Clinically Viable Heroin Vaccine.Journal of the American Chemical Society · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Brantley P JarvisJohns Hopkins University School of Medicine, United States.
Anthony DeFulioJohns Hopkins University School of Medicine, United States.
Lauren LongJohns Hopkins University School of Medicine, United States.
August F HoltynJohns Hopkins University School of Medicine, United States.
Annie UmbrichtJohns Hopkins University School of Medicine, United States.
Michael FingerhoodJohns Hopkins University School of Medicine, United States.
George E BigelowJohns Hopkins University School of Medicine, United States.
Kenneth SilvermanJohns Hopkins University School of Medicine, United States. Electronic address: ksilverm@jhmi.edu.
Johns Hopkins University · US

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Employment-Based Depot Naltrexone Clinical TrialR01DA019497 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SILVERMAN, KENNETH · 2005 to 2016
$6.3M
NIDA NIH HHS R01 DA019497NIDA NIH HHS T32 DA007209
6 · The paper itself

Abstract

BACKGROUND AND

aimExtended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks, yet many patients continue to use them. To learn more about why this occurs, we collected self-reports on subjective effects and drug use factors from participants' most recent heroin/opiate use while under XR-NTX blockade.

methodsParticipants (n=38) were unemployed, heroin-dependent adults enrolled in a randomized controlled trial evaluating employment-based incentives to promote adherence to XR-NTX. A subset of participants (n=18) were asked to complete a survey about their most recent use of heroin/opiates when they provided an opiate-positive urine sample while under XR-NTX blockade. Surveys were administered weekly, and participants could complete multiple surveys throughout the trial. Participants reported how high they were (11-point scale; 0=not at all, 10=extremely), how much heroin/opiates they took (less, more, or about the same as usual before starting naltrexone), whether they used cocaine at the same time, and the routes of administration for heroin/opiates and cocaine (if used). All analyses were descriptive.

resultsOf the 107 surveys, 75.7% indicated being "not at all" high the last time heroin/opiates were used. 75.5% of surveys reported opiate amounts that were less than usual, and only 7.5% reported amounts larger than usual. Cocaine was used at the same time as heroin for 57.9% of surveys but typically through a different route (74.2%). DISCUSSION: Using heroin/opiates while under XR-NTX blockade is not strongly associated with self-reports of high, taking larger than normal amounts of opiates, or taking opiates and cocaine simultaneously via the same route. Future research should incorporate measures of naltrexone concentration and more comprehensive and frequent assessments using ecological momentary assessment.

Indexed as

AdultBehavior, AddictiveCocaineDelayed-Action PreparationsFemaleHumansMaleNaltrexoneNarcotic AntagonistsOpiate AlkaloidsOpioid-Related DisordersPilot ProjectsRandomized Controlled Trials as TopicCocaineDelayed-Action PreparationsNaltrexoneNarcotic AntagonistsOpiate AlkaloidsBlockadeChallengeExtended-release naltrexoneHeroinOpioids

Identifiers

PMID28161142
PMCPMC5483192
OpenAlexW2561850417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.